Effects of galcanezumab on migraine severity and symptoms: post hoc analysis of Phase 3 trials


  • In people with episodic and chronic migraine, galcanezumab treatment reduces the number of monthly migraine days, the severity of migraine, and the symptoms associated with migraine compared with placebo.

Why this matters

  • Migraine is a leading cause of disability worldwide and is associated with symptoms such as nausea, vomiting, photophobia, and phonophobia.

  • Galcanezumab is a monoclonal antibody targeting the calcitonin gene-related peptide that is approved to treat migraine; however, limited data are available from Phase 3 studies that describe how galcanezumab impacts the severity and symptoms of migraine.